{{Drugbox
| verifiedrevid = 443400546
| IUPAC_name =  
| image = <!--Almagate.svg-->

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|almagate}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number = 66827-12-1
| ATC_prefix = A02
| ATC_suffix = AD03
| PubChem = 71749
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 64792
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 568Z59H7ZJ
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02821

<!--Chemical data-->
| chemical_formula = Al<sub>2</sub>Mg<sub>6</sub>(OH)<sub>14</sub>(CO<sub>3</sub>)<sub>2</sub> · 4 H<sub>2</sub>O

| molecular_weight = 314.99 g/mol
| smiles = [Al+3].[Mg+2].[Mg+2].[Mg+2].[OH-].[OH-].[OH-].[O-]C([O-])=O.[OH-].[OH-].[OH-].[OH-].O.O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/CH2O3.Al.3Mg.9H2O/c2-1(3)4;;;;;;;;;;;;;/h(H2,2,3,4);;;;;9*1H2/q;+3;3*+2;;;;;;;;;/p-9
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MTEOMEWVDVPTNN-UHFFFAOYSA-E
}}
'''Almagate''' (trade name '''Almax''') is an [[aluminium]]- and [[magnesium]]-containing [[antacid]]. It was first described in 1984.<ref>{{Cite journal
| pmid = 6548918
| year = 1984
| author = Moragues
| month =  | first = J. B.
| title = Characterization of a new crystalline synthetic gastric antacid, almagate
| volume = 34
| issue = 10A
| pages = 1346–1349
| issn = 0004-4172
| journal = Arzneimittel-Forschung
| url = http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+21645-51-2
| format = Free full text
}}</ref><ref>{{Cite journal 
| pmid = 6439224 
| year = 1984
| author = Beneyto 
| month =   | first = J. F. B. 
| title = Evaluation of a new antacid, almagate 
| volume = 34 
| issue = 10A 
| pages = 1350–1354 
| issn = 0004-4172 
| journal = Arzneimittel-Forschung 
| url = http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+21645-51-2 
| format = Free full text
}}</ref>

== Adverse effects ==
Almagate is well tolerated. In a [[clinical trial]], the most common [[adverse drug reaction|adverse effect]]s were diarrhea and nausea.<ref>{{Cite journal
| pmid = 6548926
| year = 1984
| author = Suau
| month =  | first = A. D.
| title = Treatment of gastric pyrosis with almagate in patients with and without endoscopically demonstrable duodenal ulcer. A multicentre clinical trial
| volume = 34
| issue = 10A
| pages = 1380–1383
| issn = 0004-4172
| journal = Arzneimittel-Forschung
| url = http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+21645-51-2
| format = Free full text
| last2 = Dominguez Martin
| first2 = A
| last3 = Ferrando Cucarella
| first3 = J
| last4 = Juncosa Iglesias
| first4 = L
| last5 = Muñoz Benitez
| first5 = J
| last6 = Nieto Calvet
| first6 = M
| last7 = Pérez Gieb
| first7 = J
| last8 = Pérez Mota
| first8 = A
| last9 = Pineda Garcia
| first9 = A
| last10 = Rodriguez Sanchez
| first10 = E
}}</ref>

== References ==
{{Reflist}}

{{Antacids}}

[[Category:Antacids]]
[[Category:Aluminium compounds]]
[[Category:Magnesium compounds]]


{{gastrointestinal-drug-stub}}